TH169352A - Dihydrropyridazine-3,5-dion derivatives - Google Patents
Dihydrropyridazine-3,5-dion derivativesInfo
- Publication number
- TH169352A TH169352A TH1501005269A TH1501005269A TH169352A TH 169352 A TH169352 A TH 169352A TH 1501005269 A TH1501005269 A TH 1501005269A TH 1501005269 A TH1501005269 A TH 1501005269A TH 169352 A TH169352 A TH 169352A
- Authority
- TH
- Thailand
- Prior art keywords
- salts
- inhibitor
- pharmaceutical
- pit
- dependent
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 239000003112 inhibitor Substances 0.000 claims abstract 8
- 229940079593 drug Drugs 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract 4
- 230000001419 dependent effect Effects 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract 4
- 239000011734 sodium Substances 0.000 claims abstract 4
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims abstract 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 206010003119 arrhythmia Diseases 0.000 claims abstract 2
- 230000006793 arrhythmia Effects 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 230000001684 chronic effect Effects 0.000 claims abstract 2
- 239000000199 parathyroid hormone Substances 0.000 claims abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 claims abstract 2
- 239000005426 pharmaceutical component Substances 0.000 claims abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000010452 phosphate Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 230000003449 preventive effect Effects 0.000 claims abstract 2
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 2
- 102100029797 Sodium-dependent phosphate transporter 1 Human genes 0.000 claims 2
- 101710116331 Sodium-dependent phosphate transporter 1 Proteins 0.000 claims 2
- 102100032419 Sodium-dependent phosphate transporter 2 Human genes 0.000 claims 2
- 101710116332 Sodium-dependent phosphate transporter 2 Proteins 0.000 claims 2
Abstract
คำขอใหม่ปรับปรุงวันที่ 7/03/2559 การประดิษฐ์นี้ให้ อนุพันธ์ไดไฮโดรพิริดาซีน-3,5- ไดโอน หรือ เกลือของมัน, หรือ ซอลเวท ของสารประกอบหรือเกลือดังหล่า,ยาทางเภสัชกรรม (pharmaceutical drug), องค์ประกอบทางเภสัช กรรม,สารยับยั้งตัวพาฟอสเฟทที่ขึ้นกับโซเดียม (sodium-dependent photophate tranporter inhibitor), และ สารป้องกันและ/หรือรักษาโรคสำหรับ ภาวะเลือดมีฟอสเฟตเกิน (hyperphosposphatemia),ภาวะ ฮอร์โมนต่อพาราไทรอยด์สูง (secondary hyperparathyroidism),และ ภาวะไตวายเรื้อรัง (chronic renel failure), ซึ่งประกอบรวมด้วย สารประกอบ เป็นส่วนผสมออกฤทธิ์, และ วิธีสำหรับการป้องกัน โรคและหรือการรักษาโรค. สิทธิบัตรยา New request updated 07/03/2016 this invention provides Dihydropyridazine-3,5-dion derivatives or their salts, or salts of such compounds or salts, pharmaceutical drugs (pharmaceutical drug), pharmaceutical components Karma, sodium-dependent paraphosphate inhibitors (sodium-dependent photophate tranporter inhibitor), and preventive and / or therapeutic agents for Phosphate excess blood (hyperphosposphatemia), arrhythmias High parathyroid hormone (secondary hyperparathyroidism), and Chronic renel failure, which contains active ingredients, and methods for prevention Disease and or treatment of disease. Drug patent
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH1501005269A TH1501005269A (en) | 2017-10-19 |
| TH169352A true TH169352A (en) | 2017-10-19 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002265A (en) | Use of pridopidine for treating functional decline. | |
| CU20180006A7 (en) | INDAZAOL AND AZAINDAZOL COMPOUNDS AS IRAK-4 INHIBITORS | |
| EA201892119A1 (en) | DRUGS, OBTAINED BY COMBINING AGONIST FXR AND ARB | |
| BR112016015449A8 (en) | therapeutic inhibitory compounds, pharmaceutical composition comprising them and use thereof | |
| MY174269A (en) | Dihydropyridazine-3,5-dione derivative | |
| MX2017012295A (en) | Formylated n-heterocyclic derivatives as fgfr4 inhibitors. | |
| BR112016026552A8 (en) | carboxamide derivatives, their uses, pharmaceutical composition, and combination | |
| EA201990765A1 (en) | AZAINDAZOLE COMPOUNDS FOR USE IN DAMAGE OF THE TENDON AND / OR Ligaments | |
| MX2019006843A (en) | CDK4 / 6 INHIBITOR. | |
| MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
| MY182634A (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| JOP20170148A1 (en) | Wnt inhibitors in the treatment of fibrosis | |
| AR109012A1 (en) | TRANSDERMAL ADMINISTRATION SYSTEM CONTAINING GALANTAMINE OR SALTS OF THIS | |
| JOP20190054B1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| TH169352A (en) | Dihydrropyridazine-3,5-dion derivatives | |
| EP3360581A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING PLRG1 INHIBITOR (PLEIOTROPIC REGULATOR 1) AS ACTIVE INGREDIENT | |
| WO2016092560A3 (en) | Dual release bilayer tablets comprising metformin | |
| EP3795585A4 (en) | PHARMACEUTICAL COMPOSITION INTENDED FOR PREVENTING OR TREATING CANCER COMPRISING AN LRIT2 INHIBITOR AS ACTIVE INGREDIENT | |
| TH167583A (en) | Carboxamide derivatives | |
| CL2019001046A1 (en) | Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131) | |
| TH135292A (en) | Pharmaceutical components | |
| TH1701003724A (en) | Pharmaceutical constituents for cancer treatment containing metal lactate salts. | |
| TH1501003494A (en) | PRMT5 inhibitors and their use | |
| TH168999A (en) | Inhibitors of RORC2 type heterobyclo-arylate And how to use it | |
| EP3805258A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING A CD300E INHIBITOR AS THE ACTIVE INGREDIENT |